MEDICI- t(11;14) and BCL2 expression in patients with multiple myeloma
Research type
Research Study
Full title
MEDICI - t(11;14) and BCL2 expression in patients with multiple myeloma: Prevalence, stability across lines of therapy, and concordance across sample types
IRAS ID
290824
Contact name
Charalampia Kyriakou
Contact email
Sponsor organisation
AbbVie Ltd
Duration of Study in the UK
1 years, 6 months, 31 days
Research summary
Multiple myeloma is a rare cancer caused by abnormal survival of plasma cells (blood cells). Most trial participants with multiple myeloma relapse (cancer comes back) or become refractory (non-responsive to treatment), and remission (a decrease in or disappearance of signs and symptoms of cancer) gets shorter after each line of treatment.
This study will look at the prevalence of markers, t(11;14) and BCL2 expression, in participants with newly diagnosed and relapsed or refractory multiple myeloma in a real-world setting, and provide insights for treatments targeting these specific populations.
At least 500 adult participants with confirmed newly diagnosed or relapsed/refractory multiple myeloma will be enrolled. Around 20 participants will be enrolled in the study in the United Kingdom. The study will be conducted in approximately 15-20 countries. Participants will not receive any drugs administered as part of this study. Bone marrow (BM) aspirate and whole blood samples will be collected as part of a standard of care procedure at diagnosis and at disease relapse.REC name
East of England - Cambridge East Research Ethics Committee
REC reference
21/EE/0021
Date of REC Opinion
17 Feb 2021
REC opinion
Further Information Favourable Opinion